Transcriptomics

Dataset Information

0

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation


ABSTRACT: Pegylated interferon-alpha (peg-IFNa) treatment induces molecular remissions (MR) in patients with myeloproliferative neoplasms (MPN), including partial MR (PMR) in 30-40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F vs. CALR-mutated cells and investigated the mechanisms of differential response. Retrospective analysis of MPN patients treated with peg-IFNa demonstrated that patients harboring the JAK2V617F mutation were more likely to achieve PMR than those with mutated CALR (p=0.004), while there was no significant difference in hematological response. In vitro experiments confirmed an upregulation of interferon-stimulated genes in JAK2V617F-positive 32D cells compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR- as in JAK2V617F mutant 32D cells.

ORGANISM(S): Mus musculus

PROVIDER: GSE120363 | GEO | 2018/10/29

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-10-29 | GSE120362 | GEO
2013-03-09 | GSE44961 | GEO
2013-03-09 | E-GEOD-44961 | biostudies-arrayexpress
2014-06-03 | E-GEOD-54645 | biostudies-arrayexpress
2014-06-03 | E-GEOD-54644 | biostudies-arrayexpress
2014-06-03 | GSE54644 | GEO
2014-06-03 | GSE54645 | GEO
2018-03-01 | GSE103238 | GEO
2018-03-01 | GSE103237 | GEO
| PRJNA492886 | ENA